KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Equity Average (2016 - 2025)

Biomarin Pharmaceutical's Equity Average history spans 16 years, with the latest figure at $6.1 billion for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 9.69% year-over-year to $6.1 billion, compared with a TTM value of $6.1 billion through Dec 2025, up 9.69%, and an annual FY2025 reading of $5.9 billion, up 10.7% over the prior year.
  • Equity Average for Q4 2025 was $6.1 billion at Biomarin Pharmaceutical, roughly flat from $6.0 billion in the prior quarter.
  • The five-year high for Equity Average was $6.1 billion in Q4 2025, with the low at $4.1 billion in Q1 2021.
  • Average Equity Average over 5 years is $4.9 billion, with a median of $4.8 billion recorded in 2023.
  • Biggest YoY gain for Equity Average was 29.87% in 2021; the steepest drop was 4.56% in 2021.
  • Tracing BMRN's Equity Average over 5 years: stood at $4.3 billion in 2021, then rose by 7.56% to $4.6 billion in 2022, then grew by 7.38% to $4.9 billion in 2023, then increased by 12.42% to $5.5 billion in 2024, then increased by 9.69% to $6.1 billion in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Equity Average are $6.1 billion (Q4 2025), $6.0 billion (Q3 2025), and $5.9 billion (Q2 2025).